Supriya Lifescience boosts API capacity with Rs 125cr Module E facility

Supriya Lifescience Ltd, a leading player in the pharmaceutical industry growth segment, has unveiled its latest Module E production block at its cutting-edge facility in Lote Parshuram, Maharashtra. This strategic development reinforces the company’s leadership in Active Pharmaceutical Ingredients (API) manufacturing, supporting its strategic growth objectives while meeting the rising demands of global pharmaceutical markets.

The ₹125 crore investment brings an additional API production capacity of 335 kilolitres, marking a 55% increase in the Lote Parshuram site’s total output. The facility now boasts a total capacity of 932 KLPD, a significant milestone for Supriya Lifescience Ltd. The new Module E production block exemplifies the company’s focus on scaling operations to strengthen its position in niche markets, particularly for niche therapeutic products.

A Facility Designed for Future Growth

Spanning 5,000 square metres, the new cutting-edge facility is designed with advanced technology to ensure superior process optimisation. With 33 reactors, including stainless steel and glass-lined variants ranging between 1.6 KL and 16 KL, Supriya Lifescience’s latest infrastructure promotes efficiency in API production capacity while maintaining the integrity of Active Pharmaceutical Ingredients.

Key features include:

Backward integration model to deliver economies of scale and reduce import dependence.

Gravity-based workflows for safety and product integrity.

Automated process controls for compliance with global standards.

The backward integration model is pivotal for Supriya Lifescience’s ability to control costs, improve supply chain efficiency, and secure a competitive edge in the global pharmaceutical markets.

Enhancing Innovation and R&D Capabilities

With the Module E production block, Supriya Lifescience is scaling its research and development to commercialise niche therapeutic products across critical health segments. This expansion aligns with the company’s strategic growth objectives, driving pharmaceutical industry growth by offering high-quality APIs to both innovators and generic drug manufacturers.

Dr Satish Wagh, Executive Chairman and Whole-Time Director, commented that the facility reflects Supriya Lifescience Ltd’s commitment to innovation and sustainability. He noted that Active Pharmaceutical Ingredients produced here will meet growing global demand while achieving operational efficiency through the company’s robust backward integration model.

Strengthening Leadership in Global Markets

Supriya Lifescience Ltd’s consistent investment in expanding its API production capacity reinforces its status as a reliable supplier in global pharmaceutical markets. With certifications such as USFDA, EUGMP, and Health Canada, the company’s cutting-edge facility ensures compliance with international regulatory standards while delivering superior-quality products.

By developing infrastructure to support emerging niche therapeutic products, Supriya Lifescience Ltd continues to set benchmarks in the pharmaceutical industry growth narrative. Its investments, including the state-of-the-art Module E production block, position the company to capitalise on increasing opportunities in global and domestic markets.